BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00040755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Bone Metastases
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: rebimastat
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)